The authors suggested that second-generation ALK inhibitors, such as alectinib and ceritinib, might have good efficacy for metastases of ALK-positive NSCLC because of their good permeability through the blood-brain barrier [15]. This evidence concerns the gene ALK and non-small cell lung carcinoma.